Tech Center 1600 • Art Units: 1612 1623
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17774777 | Colored particles | Final Rejection | SYMRISE AG |
| 18733216 | SKIN CARE COMPOSITION AND METHOD FOR TREATING POST-ACNE MARKS | Non-Final OA | The Procter & Gamble Company |
| 18081750 | COSMETIC COMPOSITION COMPRISING POLYACRYLATE CROSSPOLYMER-6 AND HIGH HLB NONIONIC SURFACTANT | Final Rejection | The Procter & Gamble Company |
| 17627273 | ENTERIC PROTON PUMP INHIBITOR SOFTGEL CAPSULE | Non-Final OA | R.P. Scherer Technologies, LLC |
| 18531274 | SKIN PERFECTING COMPOSITIONS | Non-Final OA | L'OREAL |
| 18091009 | CLEANSING COMPOSITIONS AND METHODS FOR USE | Final Rejection | L'Oreal |
| 17776186 | LIPOSOME COMPOSITIONS AND METHODS OF TREATMENT TARGETED TO TUMOR ENDOTHELIUM | Final Rejection | Washington University |
| 18087423 | CHEMOEMBOLIC COMPOSITIONS AND METHODS OF TREATMENT USING THEM | Final Rejection | Boston Scientific Medical Device Limited |
| 18211886 | INTRAOCULAR DELIVERY OF BIOACTIVE MOLECULES USING IONTOPHORESIS | Final Rejection | KEMIN INDUSTRIES, INC. |
| 17796914 | GAS-FILLED MICROVESICLES FOR THERAPEUTIC USE | Final Rejection | Bracco Suisse SA |
| 17282726 | MAKEUP BASE COSMETIC COMPOSITION FOR SKIN | Final Rejection | LG HOUSEHOLD & HEALTH CARE LTD. |
| 18685701 | STABLE GABAPENTIN POWDER | Non-Final OA | Avion Phamaceuticals, LLC |
| 17999486 | HYDROPHOBIC ANTIMICROBIAL AGENTS | Final Rejection | OMYA INTERNATIONAL AG |
| 18257464 | PHARMACEUTICAL COMPOSITION FOR TREATING CDI COMPRISING CLAY MINERAL COMPLEX, AND METHOD FOR PRODUCING SAME | Non-Final OA | KOREA INSTITUTE OF GEOSCIENCE AND MINERAL RESOURCES |
| 17228826 | HYDROGEN PEROXIDE DISINFECTANT COMPOSITION | Non-Final OA | Metrex Research LLC |
| 18454177 | METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Non-Final OA | KARUNA THERAPEUTICS, INC. |
| 18255964 | TWO-PHASE COSMETIC COMPOSITION COMPRISING AN AMINO ACID AND TWO SPECIFIC ACIDS | Final Rejection | L’OREAL |
| 18265652 | MEDICINE FOR RELIEVING OR ELIMINATING PROTRACTED OPIOID ABSTINENCE SYNDROME AND PREPARATION METHOD THEREFOR | Non-Final OA | Shenzhen ScienCare Pharmaceutical Co., Ltd. |
| 17435520 | COMPOSITION FOR USE IN THE PREVENTION AND/OR TREATMENT OF DYSBIOSIS | Final Rejection | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT |
| 18159030 | MULTIPLE NUTRIENT LIPOSOMAL SUPPLEMENT AND METHODS OF MANUFACTURING THE SAME | Final Rejection | Nutraceutical Corporation |
| 18002880 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF COVID-19 | Final Rejection | PROTHIONE, LLC |
| 17754738 | LONG-ACTING INJECTABLE FORMULATIONS OF KETAMINE PAMOATE SALTS | Final Rejection | ALAR PHARMACEUTICAL INC. |
| 17431807 | ORODISPERSIBLE FORMULATIONS | Final Rejection | Millicent Pharma Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy